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CD8+ T cell responses are major players of tumor eradica-
tion in various vaccination protocols. However, an opti-
mal stimulation of CD4+ T helper cells is required for
both priming and maintenance of the effector CTL
response against the tumor. In this study we show that the
murine mammary adenocarcinoma cell line TS/A, a
highly malignant MHC-II-negative tumor, is rejected in
vivo if genetically engineered to express MHC-II mole-
cules by transfer of the MHC-II transactivator CIITA. TS/A-
CIITA cells are fully rejected by 93% of the syngeneic
recipients and have a significantly lower growth rate in the
remaining 7% of animals. Rejection requires CD4+ and
CD8+ cells. CD4+ T cells are fundamental in the priming
phase, whereas CTLs are the major anti-tumor effectors.
All tumor rejecting animals are protected against rechal-
lenge with the parental TS/A tumor. Immunohistochemi-
cal data at day 5 post-inoculation showed an higher
infiltrate of CD4+ T cells in mice bearing TS/A-CIITA, than
in mice bearing the TS/A tumor. Subsequently, from day
7 trough day 10, TS/A-CIITA tumors showed higher
number of both CD4+ and CD8+ cells, dendritic cells,
together with massive necrosis. The frequency of IFN-α-
secreting splenocytes early after inoculations was also
assessed by an ex vivo ELISPOT assay. Only the rejecting
TS/A-CIITA animals showed an high frequency of IFN-α-
secreting cells (between 80 and 120/106 splenocytes).
Importantly, CD4 and CD8 depletion experiments
revealed that at the time of tumor resolution the major
cell population recognizing the TS/A-CIITA cells was of
CD4 origin. This is the first example of successful tumor
vaccination by genetic transfer of CIITA. These results
open the way to a possible use of CIITA for increasing
both the inducing and the effector phase of the anti-tumor
response.
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